MBIO - Mustang Bio shares rise 4% after $2M NIH grant

Mustang Bio (NASDAQ:MBIO) has been awarded a grant of ~$2M from the National Cancer Institute of the National Institutes of Health (NIH). Shares up more than 4% premarket. The two-year grant will partially fund the company's early-stage trial of MB-106 for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (NHL) or chronic lymphocytic leukemia (CLL). Mustang Bio had announced updated interim data from Phase 1/2 trial of MB-106 for high-risk B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia (CLL).

For further details see:

Mustang Bio shares rise 4% after $2M NIH grant